|Mr. Michael J. Higgins M.B.A.||Interim CEO & Chairman||90k||N/A||1962|
|Dr. Glenn F. Pierce||Independent Director, Interim Chief Scientific Officer & Chief Medical Officer||51.5k||N/A||1956|
|Mr. Robert W. Hesslein||Sr. VP & Gen. Counsel||580.65k||N/A||1953|
|Mr. G. Andre Turenne||Advisor||873.48k||N/A||1974|
|Dr. Steven M. Paul M.D.||Exec. Science Advisor & Director||44k||N/A||1951|
|Dr. Krystof Bankiewicz M.D., Ph.D.||Founder||N/A||N/A||N/A|
|Dr. Guangping Gao||Founder||N/A||N/A||N/A|
|Dr. Mark A. Kay M.D., Ph.D.||Founder||N/A||N/A||1958|
|Dr. Phillip D. Zamore||Founder||N/A||N/A||N/A|
|Ms. Allison Dorval||CFO & Principal Accounting Officer||N/A||N/A||1976|
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Voyager Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.